CAS 956014-19-0

Thiourea, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazol-5-yl)phenyl]-

CAS: 956014-19-0

Formel: C₁₆H₉BrF₆N₆S

Reinheit: 95%

Farbe und Form: Solid

Molekulargewicht: 511.2423

Ref: IN-DA003621

1-(3,5-Bis(Trifluoromethyl)Phenyl)-3-(4-Bromo-2-(2H-Tetrazol-5-Yl)Phenyl)Thiourea

CAS: 956014-19-0

1-(3,5-Bis(Trifluoromethyl)Phenyl)-3-(4-Bromo-2-(2H-Tetrazol-5-Yl)Phenyl)Thiourea

Reinheit: 95%

Molekulargewicht: 511.24g/mol

Ref: 54-PC108593

NS 11021

CAS: 956014-19-0

NS 11021

Reinheit: ≥95%

Molekulargewicht: 511.24g/mol

Ref: 54-BUP05521

NS 11021

CAS: 956014-19-0

NS 11021 (NS11021) , a novel opener of large-conductance Ca(2+)-activated K(+) channels

Formel: C₁₆H₉BrF₆N₆S

Reinheit: 97.26%

Farbe und Form: Solid

Molekulargewicht: 511.24

Ref: TM-T4294

1-[3,5-bis(trifluoromethyl)phenyl]-3-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]thiourea

CAS: 956014-19-0

Reinheit: 95%

Molekulargewicht: 511.2399902

Ref: 10-F812004

NS 11021

Kontrolliertes Produkt

CAS: 956014-19-0

Formel: C₁₆H₉BrF₆N₆S

Farbe und Form: Neat

Molekulargewicht: 511.242

Ref: TR-N926033

NS 11021

CAS: 956014-19-0

NS 11021 is a drug that inhibits the mitochondrial membrane potential, which is the driving force for ATP synthesis. It can be used to treat bowel disease and cardiac diseases such as hypertrophic cardiomyopathy. NS 11021 also has a pharmacological effect on channels that open in response to an increase in cytosolic calcium levels. This includes atrial and activated potassium channels, which are important for the propagation of action potentials in the heart. NS 11021 can also be used to treat experimental models of ischemia–reperfusion injury due to its ability to inhibit energy metabolism.

Formel: C₁₆H₉BrF₆N₆S

Reinheit: Min. 95%

Molekulargewicht: 511.24 g/mol

Ref: 3D-GNB01419